New insights into the thrombopoietic status of patients on dialysis through the evaluation of megakaryocytopoiesis in bone marrow and of endogenous thrombopoietin levels.
The thrombopoietic status of patients with uremia remains unclear. This issue was addressed with particular reference to marrow megakaryocytopoiesis and endogenous thrombopoietin (TPO) levels. A study was conducted in 114 patients on hemodialysis, 43 patients on continuous ambulatory peritoneal dialysis, and 48 age-matched controls. Reticulated platelets, a marker of marrow megakaryocytopoiesis, were measured by flow cytometry. Serum TPO levels, platelet-associated IgG (PAIgG) levels, and hepatitis C virus (HCV) antibody titers were also measured by enzyme-linked immunosorbent assay. Circulating and reticulated platelet counts were significantly lower in the patients on dialysis than in the controls. Thrombocytopenia (less than 150 x 10(9)/L) was most frequent in the HCV-positive hemodialysis patients, who had a higher incidences and higher PAIgG titers. The following results were obtained in the HCV-negative dialysis patients: (1) platelet counts chronologically decreased with years on hemodialysis; (2) platelet counts were associated with the reticulated platelet counts; (3) serum TPO levels were significantly elevated in the dialysis patients, responding to the decrease of reticulated platelets; (4) hematocrits had a positive correlation with serum TPO levels, and serum TPO levels were significantly higher in the patients on hemodialysis who did not require recombinant human erythropoietin therapy than in the other patients. In conclusion, thrombocytopenia is a frequent finding in patients on dialysis. The failure of megakaryocyte production could be the principal cause of the platelet reduction, and the peripheral destruction and sequestration of platelets may be concomitantly involved. Elevation of serum TPO may in part serve as an aid to erythropoiesis in dialysis patients.
Ando
M
M
Division of Nephrology, Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan. aannddoo@f3.dion.ne.jp
Iwamoto
Y
Y
Suda
A
A
Tsuchiya
K
K
Nihei
H
H
D000328:Adult; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D016824:Antigens, Human Platelet / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D001792:Blood Platelets / Q000276:immunology / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology*; D004921:Erythropoietin / Q000097:blood / Q000627:therapeutic use; D005434:Flow Cytometry; D006400:Hematocrit; D016174:Hepacivirus / Q000276:immunology; D006526:Hepatitis C / Q000097:blood / Q000150:complications; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy; D008533:Megakaryocytes / Q000473:pathology*; D008875:Middle Aged; D010976:Platelet Count; D011994:Recombinant Proteins / Q000627:therapeutic use; D006435:Renal Dialysis / Q000009:adverse effects*; D013921:Thrombocytopenia / Q000209:etiology*; D013926:Thrombopoietin / Q000097:blood*
D016824:Antigens, Human Platelet; D001323:Autoantibodies; D018937:Hepatitis C Antibodies; D007074:Immunoglobulin G; D011994:Recombinant Proteins; D004921:Erythropoietin; D013926:Thrombopoietin